The authors intend this brief monograph, The Epilepsies for medical students and physicians not primarily involved in the neurological specialties. They have produced a concise and readable review of the subject, but the cost ($6) seems excessive for such a small offering.
Some of the drugs recommended are not available in the United States (sulthiame [Ospolot] and nitrazepam [Mogadon]); carbamazepine (Tegretol) is marketed only for the treatment of trigeminal neuralgia. The dosage of diphenylhydantoin (Dilantin) recommended for children under one year of age (20 mg two or three times daily) would be quite likely to result in toxicity. This drug is difficult to use in the treatment of young children because of the narrow margin between therapeutic and toxic dosage. Phenobarbital is not given the prominent position which I feel it deserves, as a keystone in seizure prevention and as a major agent for treatment of status epilepsy.